NICE Recommends Tisagenlecleucel for Relapsed/Refractory DLBCL

February 1, 2019 – The UK’s National Institute for Health and Care Excellence has authorized the use of the CAR T-cell therapy tisagenlecleucel for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received ≥2 lines of chemotherapy.1 The treatment will be made available through the Cancer Drugs Fund. “Recommending another revolutionary CAR T-cell therapy for adults with lymphoma represents a step … (leggi tutto)